NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BigBear.ai Holdings, Inc. (NYSE: BBAI) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in BigBear.ai, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/bigbearai-holdings-inc. Investors have until June 10, 2025, to ask the Court to be a ...

Core Viewpoint - A lawsuit has been filed against Viatris Inc. and certain senior executives for potential violations of federal securities laws, stemming from misleading statements regarding the company's operational conditions and the impact of a failed FDA inspection [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Western District of Pennsylvania, titled Quinn v. Viatris Inc., et al., No. 25-cv-466, with investors having until June 3, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Viatris securities [2]. Group 2: Company Background and Allegations - Viatris is a global healthcare company that provides medicines to approximately 1 billion patients across over 165 countries [3]. - The complaint claims that Viatris misrepresented its facilities as being in "good operating condition" and suitable for their intended purposes, while downplaying the significance of a Warning Letter issued by the FDA following a failed inspection at its Indore, India facility [3][4]. Group 3: Financial Impact - The failed FDA inspection has had a substantial negative impact on Viatris's financial results, hindering the company from manufacturing and distributing key products, including Lenalidomide [4]. - In the Q4 2024 results released on February 27, 2025, Viatris disclosed that the failed inspection would reduce 2025 revenue by approximately $500 million and earnings from operations by about $385 million [5]. - Following this announcement, Viatris's stock price fell roughly 15%, from $11.24 per share on February 26, 2025, to $9.53 per share on February 27, 2025 [5].

Core Viewpoint - A lawsuit has been filed against The Bancorp, Inc. and its senior executives for potential violations of federal securities laws, specifically related to misrepresentation of risks associated with its loan portfolio [1][2][4]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of Delaware, captioned Linden v. The Bancorp, Inc., et al., No. 25-cv-00326, with investors having until May 16, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, representing investors who purchased Bancorp stock [2]. Group 2: Company Overview - Bancorp is a financial holding company involved in institutional banking, commercial real estate bridge lending, small business lending, and commercial fleet leasing, with its REBLs primarily collateralized by apartment buildings [3]. Group 3: Allegations of Misrepresentation - The complaint claims that Bancorp misrepresented the risks of default or loss on its REBL loan portfolio and that its credit loss methodology was inadequate [4]. - It is alleged that Bancorp's internal controls over financial reporting contained at least one material weakness [4]. Group 4: Stock Performance and Impact - Following a report from Culper Research on March 21, 2024, which highlighted misrepresentations regarding the REBL loan portfolio, Bancorp's stock price fell over 10%, from $36.04 to $32.12 [5]. - On October 24, 2024, Bancorp reported a net income of $51.5 million, leading to a 14% decline in stock price from $54.96 to $47.01 due to increased credit losses [6]. - On March 4, 2025, Bancorp disclosed inappropriate filing of its Annual Report, causing a 4.4% drop in stock price from $53.59 to $51.25 [7].

NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Fluence Energy, Inc. (NASDAQ: FLNC) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Fluence Energy, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/fluence-energy-inc. Investors have until May 12, 2025, to ask the Court to be appoi ...

Core Viewpoint - A securities class action lawsuit has been filed against Fluence Energy, Inc. for misleading investors regarding its financial health and relationships with major partners during the specified Class Period [1][3]. Group 1: Lawsuit Details - The lawsuit pertains to Fluence securities purchased between October 28, 2021, and February 10, 2025 [1][2]. - Investors have until May 12, 2025, to seek appointment as lead plaintiff representatives [2]. Group 2: Allegations Against Fluence - The lawsuit claims that Fluence misled investors about the stability of its relationships with Siemens AG and The AES Corporation, which are significant sources of revenue [3]. - Allegations include that Siemens accused Fluence of engineering failures and fraud, leading to artificially inflated margins and revenue growth due to the impending decline in these relationships [3].

Core Viewpoint - PTC Therapeutics, Inc. is under investigation for potential securities fraud and unlawful business practices following the announcement of Phase 2 study results for its treatment of Huntington's disease, which led to a significant drop in stock price [1][2][3]. Group 1: Company Developments - PTC announced results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington's disease patients, achieving its primary endpoint of reducing blood Huntingtin protein levels with a p-value of less than 0.0001 at Week 12 [2]. - Despite meeting the primary endpoint, analysts suggest that a Phase 3 study may be necessary to confirm the treatment's efficacy in slowing the progression of Huntington's disease [2]. Group 2: Market Reaction - Following the announcement of the study results, PTC's stock price fell by $9.30 per share, representing an 18.62% decline, closing at $40.65 per share on May 5, 2025 [3].

Core Viewpoint - Integra LifeSciences Holdings Corporation is under investigation for potential securities fraud and unlawful business practices following disappointing financial results and significant stock price decline [1][2][3]. Financial Performance - For Q1 2025, Integra reported earnings per diluted share of -$0.33, a decline from -$0.04 per diluted share in the same period last year [2]. - The company provided full-year earnings guidance and a second-quarter revenue outlook that fell significantly short of consensus estimates [2]. - Declines were noted in the Neurosurgery and Tissue Technologies segments, attributed to inventory issues and slower ordering patterns [2]. Stock Market Reaction - Following the announcement of the financial results, Integra's stock price dropped by $3.57 per share, or 21.19%, closing at $13.28 per share on May 5, 2025 [3].

LOS ANGELES, May 6, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of Organon & Co. ("Organon" or "the Company") (NYSE: OGN) for violations of the securities laws.INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors. As part of its Q1 2025 earnings release, Organon announced it was slashing its quarterly dividend by approximately 90% despite pr ...

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Arvinas, Inc. and its officers or directors [1] Group 1: Company Developments - On May 1, 2025, Arvinas announced the removal of plans for a Phase 3 first-line combination trial with atirmociclib and a second-line combination trial with a CDK4/6 inhibitor from its joint development plan with Pfizer [2] - The decision to remove these trials was based on a review of emerging information, external data results, the evolving treatment landscape in metastatic breast cancer, and long-term capital allocation [2] - Arvinas also announced a workforce reduction of approximately one-third to streamline operations and enable efficient progression of its portfolio, with completion planned for the second quarter of 2025 [2] - Following this news, Arvinas's stock price fell by $2.39 per share, or 24.84%, closing at $7.23 per share on May 1, 2025 [2]

NEW YORK, May 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SelectQuote, Inc. ("SelectQuote" or the "Company") (NYSE: SLQT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether SelectQuote and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action]On May 1, 2025, the U ...